GlassScriptPhysician profile
Caroline Hufford Bone
NPI 1063977296
$5,383.11
in general payments reported to CMS, 2019-2025
28 companies · $762 in 2025
The $762 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $979 · 2022: $1,079 · 2023: $1,518 · 2024: $1,045 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,324.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,093.86 | 2021-2025 | |
| Abbvie INC. | $910.72 | 2021-2025 | |
| Incyte Corporation | $454.18 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $449.86 | 2021-2024 | Dupixent |
| Janssen Biotech, INC. | $378.82 | 2021-2023 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $345.73 | 2023-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $229.89 | 2021-2025 | Aklief, Nemluvio |
| Novartis Pharmaceuticals Corporation | $228.45 | 2021-2025 | |
| Amgen INC. | $213.72 | 2021-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $171.56 | 2021-2024 | Winlevi |
| Almirall LLC | $130.65 | 2021-2025 | Seysara, Klisyri |
| Pfizer INC. | $117.79 | 2021-2024 | |
| Lilly USA, LLC | $114.41 | 2021-2024 | Taltz, Ebglyss |
| Dermavant Sciences, INC. | $82.06 | 2023-2024 | Vtama |
| Botanix Sb INC | $73.40 | 2025 | Sofdra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $59.55 | 2021 | |
| Ucb, INC. | $50.75 | 2022-2024 | Bimzelx, Cimzia |
| Verrica Pharmaceuticals INC. | $44.56 | 2024-2025 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.51 | 2022-2023 | Cyltezo |
| Epi Health, LLC | $37.21 | 2021-2022 | |
| Leo Pharma INC. | $35.55 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $21.38 | 2023-2024 | |
| Paratek Pharmaceuticals, INC. | $21.19 | 2024 | Nuzyra |
| Kyowa Kirin, INC. | $16.34 | 2021 | |
| Celgene Corporation | $15.59 | 2021 | |
| Arcutis Biotherapeutics, INC. | $15.30 | 2024 | Zoryve |
| Nabriva Therapeutics, Plc | $13.99 | 2022 | |
| Organon LLC | $13.09 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Bone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.